Kerry Group’s probiotic strain Sporevia (Bacillus subtilis MB40) can eliminate Staphylococcus aureus in the human body by more than 95 percent, a clinical trial has found. Staphylococcus aureus (S. aureus), commonly known as “staph,” is a pathogen that caused over 119,000 infections and nearly 20,000 deaths in the US in 2017.1 However, the use of oral antibiotics for staph decolonization is advised against because of its effect on the gut microbiota and antibiotic resistance.2 Sporevia … [Read more...] about Sporevia probiotic can reduce staph colonization by more than 95%, study finds
Kerry
Kerry and c-LEcta enter agreement to market DENARASE® products
28 February 2023: Kerry, a world leader in taste and nutrition, and c-LEcta, a leading biotechnology company in enzyme engineering and bioprocess development, have announced a new partnership to jointly market DENARASE® products. The DENARASE® product family was launched in 2012 and applied in hundreds of clinical and commercial production processes for gene/cell therapies and vaccines. Combining Kerry and c-LEcta’s expertise in the biopharma and pharmaceutical sectors, the partnership will … [Read more...] about Kerry and c-LEcta enter agreement to market DENARASE® products
Kerry and Kameda Seika announce new exclusive licensing agreement for Japanese rice-derived postbiotic
Kerry, a world leader in taste and nutrition, has announced a new commercial agreement with Japan-based Kameda Seika to market and distribute the company’s rice-derived postbiotic exclusively in the Americas and Europe across a range of applications. Kameda Seika is a leading global rice cracker company with decades of rice research experience. Kameda has extensively researched rice-based lactobacillus for over 25 years and has accumulated several health claims. Kameda’s postbiotic … [Read more...] about Kerry and Kameda Seika announce new exclusive licensing agreement for Japanese rice-derived postbiotic
